my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
13-06-2008: Leaders of the 1000 Genomes Project announced that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: Applied Biosystems, an Applera Corporation business; 454 Life Sciences, a Roche company ; and Illumina Inc. in San Diego.
The 1000 Genomes Project, which was announced in January 2008, is an international research consortium that is creating a new map of the human genome that will provide a view of biomedically relevant DNA variations at a resolution unmatched by current resources. Organizations that have already committed major support to the project are: the Beijing Genomics Institute, Shenzhen, China; the Wellcome Trust Sanger Institute, Hinxton, Cambridge, U.K.; and the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. The NHGRI-supported work is being done by the institute's Large-Scale Sequencing Network, which includes the Human Genome Sequencing Center at Baylor College of Medicine, Houston; the Broad Institute of MIT and Harvard, Cambridge, Mass.; and the Washington University Genome Sequencing Center at Washington University School of Medicine, St. Louis.
The 1000 Genomes Project builds upon the International HapMap Project, which produced a comprehensive catalog of human genetic variation - variation that is organized into neighborhoods called haplotypes. The HapMap catalog laid the foundation for the recent explosion of genome-wide association studies that have identified more than 130 genetic variants linked to a wide range of common diseases, including type 2 diabetes, coronary artery disease, prostate and breast cancers, rheumatoid arthritis, inflammatory bowel disease and a number of mental illnesses.
The HapMap catalog, however, only identifies genetic variants that are present at a frequency of 5 percent or greater. The catalog produced by the 1000 Genomes Project will map many more details of the human genome and how it varies among individuals, identifying genetic variants that are present at a frequency of 1 percent across most of the genome and down to 0.5 percent or lower within genes. The 1000 Genomes Project's high-resolution catalog will serve to accelerate many future studies of people with specific illnesses.
Watchlist
This is where you can add this news to your personal favourites
Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares
The majority shareholder of GENEART AG, Regensburg, Applied Biosystems Deutschland GmbH, Darmstadt ("ABD"), directly holds more than 95% of all shares in GENEART AG as noticed by ABD. ABD informed the management board of GENEART AG about this fact by letter dated August/3/2010. By virtue o ... more
GENEART AG and Applied Biosystems Deutschland GmbH intend to conclude a domination agreement
GENEART AG and its majority shareholder, Applied Biosystems Deutschland GmbH, intend to conclude a domination agreement pursuant to Section 291 et seq. German Stock Corporation Act (Aktiengesetz) with GENEART AG as the dominated entity and Applied Biosystems Deutschland GmbH as the dominati ... more
Management Board and Supervisory Board of GENEART Recommends Acceptance of Voluntary Public Offer
The Management Board and the Supervisory Board of GENEART AG have announced their joint statement with respect to the voluntary public offer by Applied Biosystems Deutschland GmbH to the shareholders of GENEART AG. This joint statement is in reference to the offer document published by the ... more
Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and ... more
Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and ... more
Applied Biosystems Deutschland GmbH
Applied Biosystems, Applera Deutschland GmbH, is a leading supplier for life science technology in the field of genomics, proteomics, high throughput screening and laboratory information management systems (LIMS). more
Roche Steps Back from Illumina Acquisition
F. Hoffman-La Roche dropped its bid to buy Illumina after Illumina’s shareholders made it clear at the company’s annual meeting that the terms were inadequate. Roche had made a $51 per share tender offer for San Diego-based Illumina, but allowed the offer to expire. GlobalData analyzed the ... more
Illumina to Open Latin America Office
Illumina, Inc. announced that the company will open an office in Sao Paolo, Brazil, to focus on developing business opportunities across Latin America. The office will open on February 1, 2011.“We’re excited about the potential for expanding our business in Latin America, where Illumina’s ... more
Researchers from Illumina, Inc. and the Wellcome Trust Sanger Institute have used Illumina's next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging ... more
Applied Biosystems, 454 Life Sciences and Illumina Join 1000 Genomes Project
Leaders of the 1000 Genomes Project announced that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: Appl ... more
BIOTECON Diagnostics signs license agreement with Applera Corporation
Applera and BIOTECON Diagnostics (BCD) announced a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. In ... more
Applied Biosystems Surpasses Industry Milestone in Lowering the Cost of Sequencing Human Genome
Applied Biosystems, an Applera Corporation business, announced a significant development in the quest to lower the cost of DNA sequencing. Scientists from the company have sequenced a human genome using its next-generation genetic analysis platform. The sequence data generated by this proje ... more
Roche Announces Thomas Schinecker as New President of 454 Life Sciences
454 Life Sciences, a center of excellence of Roche’s business unit Applied Science, announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates ... more
Deadly E. Coli Strain Sequenced with Roche GS Junior System by HPA Scientists
The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences’ benchtop GS Junior sequencing system to generate the “most accurate and detailed genetic analysis to date” of this particularly virulent strain. The seq ... more
Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research
RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for simple and cost-effective investigation of drug absorption, distribution, metabolism, and excr ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
